Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Executes the first project for developing and manufacturing a novel anticancer mAb
Subscribe To Our Newsletter & Stay Updated
